Lutetium Lu 177 monoclonal antibody CC49

N/A

Report date: 2025/10/20 14:38:41

Base Information

Drug NameLutetium Lu 177 monoclonal antibody CC49

Drug Alias Name177Lu-CC49

ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionTumor-associated glycoprotein 72 binders

TargetsTumor-associated glycoprotein 72

Therapy Area/IndicationsOvarian NeoplasmsAbdominal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Cancer Institute

Active IndicationsN/A

Inactive IndicationsOvarian NeoplasmsAbdominal Neoplasms

Other Information

ATC CodeN/A